Using Artificial Intelligence to Improve Diagnosis and Treatment for Kids with Cancer
What is artificial intelligence? Artificial intelligence (AI) is a technology that can simulate human intelligence characteristics including learning, predicting, analyzing, and deriving solutions using data. AI was first defined in 1956, but the use of the technology was limited through the early 2000s due to poor computer performance and other economic factors. In the 2010s,…
Developing and improving models for testing new treatments for kids with cancer
Brain and spine tumors are one of the most common forms of cancer found in kids, second only to leukemia. Despite significant advances in treatment, brain tumors remain the leading cause of cancer-related death in children. The kids who do survive often suffer from long-term side effects from treatment, and face the risk of recurrence…
Colorado researchers receive international recognition for groundbreaking kids’ cancer research at ISPNO 2022
More than a dozen doctors and researchers from the Morgan Adams Foundation Pediatric Brain Tumor Research Program were invited to present their work at the largest global conference in pediatric neuro-oncology. The 20th International Symposium on Pediatric Neuro-Oncology was held June 13-15 in Hamburg, Germany. ISPNO is the major global meeting for the international community…
MAF-funded researchers present at ISPNO 2022
The 20th International Symposium on Pediatric Neuro-Oncology was held June 13-15, 2022 in Hamburg, Germany. ISPNO is the major global meeting for the international community of professionals involved in the scientific research, diagnosis, treatment, and rehabilitation of kids and teens with brain and central nervous system cancers. Doctors and researchers from the Morgan Adams Foundation…
Give Kids a Chance Act Aims to Expand Pediatric Cancer Research and Clinical Trials
The Give Kids a Chance Act is a bill that aims to encourage clinical trials that use combinations of drugs for kids with cancer. To date, testing new pediatric cancer treatments has not been a priority for the pharmaceutical industry because there is more potential revenue in treating adult cancers. The Give Kids a Chance…
artma 2022 Kid Art
artma exists because there are kids with cancer who are fighting every day to survive. For each artma, Patricia Mowry, the Creative Arts Therapist at Children’s Hospital Colorado, coordinates an art project with kids in treatment in the Pediatric Center for Cancer and Blood Disorders. This year, 20 kids, teens, and young adults participated by creating a…
Unleashing the Immune System to Treat Pediatric Cancer
Immunotherapy is a type of biological therapy that utilizes the patient’s immune system to fight cancer. Over the last decade, immunotherapy has been proven as a viable treatment for a range of cancers. One form of immunotherapy, called CAR-T cell therapy, has shown a high level of success for leukemia and lymphoma patients. As you…
2022 Research Funded
Thanks to the support of generous donors, 28 projects have received funding for 2022. These projects address the widest range of pediatric cancers and represent the largest single-year financial support in the history of The Morgan Adams Foundation. This groundbreaking research has the potential to change the landscape for kids with cancer. The projects are…
What Donors Made Possible in 2021
Progress in medical research takes time — and it is only possible through funding and support of people who care. It can be difficult to wait for results. And that’s a million times harder if you know a child with cancer who needs a treatment that works right now. But progress IS happening. Advancements are…
Five new clinical trials for kids with cancer
Progress in medical research takes time – and requires sustained funding. Support for kids’ cancer research is critically important. Donations from caring individuals make possible studies into safer and more effective treatments for kids and teens. Without donor generosity, the good ideas doctors and researchers have would never make it out of the lab and into…